(Q38037493)

27 August 2017

Can immuno-oncology offer a truly pan-tumour approach to therapy? (English)

1 reference

27 August 2017

1 reference

A M M Eggermont

1

1 reference

27 August 2017

1 September 2012

1 reference

27 August 2017

1 reference

27 August 2017

23 Suppl 8

1 reference

27 August 2017

viii53-7

1 reference

Cancer immunotherapy: the past, the present and the future

27 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

The biology of cancer testis antigens: putative function, regulation and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

Mechanisms of immune evasion by tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

Does the immune system see tumors as foreign or self?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

Immune surveillance of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

Systematic review of medical treatment in melanoma: current status and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

Tumor-driven evolution of immunosuppressive networks during malignant progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

Immunosuppressive networks in the tumour environment and their therapeutic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

Vaccines against human carcinomas: strategies to improve antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

T cells take aim at cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

Immunogenic and tolerogenic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

Systemic effects of local radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

Estimates of cancer incidence and mortality in Europe in 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

Tumor immunosurveillance in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

Confidence intervals for the effect of a prognostic factor after selection of an 'optimal' cutpoint.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

The prognostic impact of anti-cancer immune response: a novel classification of cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

TNM staging in colorectal cancer: T is for T cell and M is for memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS264

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS264

1 reference

27 August 2017

1 reference

PubMed ID

22918930